Allogene Therapeutics IPO

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic CAR T-cell therapies for cancer treatment. Unlike autologous CAR-T therapies that use a patient's own cells, Allogene's approach uses healthy donor cells that are genetically modified to create 'off-the-shelf' treatments that can be manufactured at scale and administered to multiple patients. This approach potentially reduces treatment timelines from weeks to days and could make CAR-T therapy more accessible and cost-effective.

The company went public in October 2018 and has multiple programs in clinical trials targeting various blood cancers and solid tumors. Allogene uses gene editing technologies including TALEN to modify donor T-cells, removing genes that could cause rejection while enhancing their cancer-fighting capabilities. Their lead programs target CD19 for relapsed/refractory non-Hodgkin lymphoma and acute lymphoblastic leukemia, with additional programs targeting other cancer antigens in development.